ロード中...
A Pooled Analysis of Two Phase 3 Clinical Trials of Dalfampridine in Patients with Multiple Sclerosis
Background: Two phase 3 clinical trials demonstrated that dalfampridine extended-release 10-mg tablets (D-ER), twice daily, significantly improved walking relative to placebo in patients with multiple sclerosis (MS). The objective of this study was to evaluate the efficacy and safety of D-ER in pati...
保存先:
| 主要な著者: | , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
The Consortium of Multiple Sclerosis Centers
2014
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4204376/ https://ncbi.nlm.nih.gov/pubmed/25337058 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7224/1537-2073.2013-023 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|